ETH-LAD

ETH-LAD

ETH-LAD

Psychoactive Research chemicals are new synthetic substances that are structurally similar to the original drug, while being functional analogs. Research on the effects of, and treatment for, abuse of these drugs is limited due to the fact that they’re fairly new and have avoided mainstream notice. Research chemicals do not have a lot of human consumption data, and thus harm-reduction and special care should be taken if choosing to ingest them.

Psychedelics are drugs which cause profound changes in a one’s perceptions of reality, otherwise known as hallucinations. While under the influence of hallucinogens, users might see images, hear sounds or feel sensations. These chemicals offer some of the most intense psychological experiences and care should be taken when ingesting them.

Disclaimer: Psychedelic drugs offer some of the most power and intense psychological experiences. Additionally these substances are illegal in many places. We understand that even though these substances are illegal, their use occurs frequently. We do not condone breaking of the law. By providing accurate information about these substances, we encourage the user to make responsible decisions and practice harm reduction.

Read the full disclaimer here.

Practice Harm Reduction. Proceed with Caution.

Description

ETH-LAD

Also known as:

  • (8β)-N,N,6-Triethyl-9,10-didehydroergolin-8-carboxamid[German][ACD/IUPAC Name]
  • (8β)-N,N,6-Triethyl-9,10-didehydroergoline-8-carboxamide[ACD/IUPAC Name]
  • (8β)-N,N,6-Triéthyl-9,10-didéhydroergoline-8-carboxamide[French][ACD/IUPAC Name]
  • Ergoline-8-carboxamide, 9,10-didehydro-N,N,6-triethyl-, (8β)-[ACD/Index Name]
  • N-ETHYLNORLYSERGIC ACID N,N-DIETHYLAMIDE
  • 6-ethyl-9,10-didehydro-ergoline-8-carboxylic acid diethylamide
  • 7-Ethyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinoline-9-carboxylic acid diethylamide
  • Ergoline-8-carboxamide, 9,10-didehydro-N,N,6-triethyl-, (8b)-
  • ETH-LAD
  • N,N,6-triethyl-9,10-didehydroergolin-8-carboxamide[ACD/IUPAC Name]
  • N-Ethyl Norlysergic Acid N,N-Diethylamide

A psychedelic drug and slightly more potent analogue of LSD, first synthesised by Alexander Shulgin - sometimes described as being less ‘abrasive’ than LSD. Less common than the associated AL-LAD, though has seen some popularity since its release on the Internet research chemical scene in 2015.

Summary

ETH-LAD is chemically similar to LSD and has a similar mechanism of action, acting primarily by stimulating serotonin receptors in the brain. The human use of ETH-LAD was first documented by Alexander Shulgin in his 1997 book TiHKAL ("Tryptamines I Have Known and Loved"). It is noted for its "modified visual distortion" relative to LSD.

It has been marketed alongside psychedelic lysergamides like 1P-LSD and AL-LAD as a legal, grey-market alternative to LSD, and commercially distributed through online research chemical vendors. ETH-LAD has been shown to be moderately to significantly more potent than LSD itself in animal studies with an active dose reported at between 40 and 100 micrograms. Anecdotal reports suggest that while it produces similar effects to LSD at low to common doses, it displays a notably divergent effects profile at higher doses, sometimes described as producing “algorithmic” and “warped” visual and auditory distortions, combined with a more “introspective” and “analytical”, if not more “neutral” head space.

ETH-LAD has also been reported to more readily produce adverse physical effects such as severe and persisting nausea, temperature dysregulation, and generalized bodily discomfort, particularly at higher doses. This has been speculated to owe itself to an unusually sensitive and unpredictable dose-response curve, as low to common dose experiences are generally described as being very manageable and non-threatening. Very little data exists about the pharmacological properties, metabolism, and toxicity of ETH-LAD, and it has little history of human usage.

Along with its sensitive dose-response and potentially concerning physical side effects, many reports suggest that this substance may be overly difficult to use safely for those who are not experienced with hallucinogens. It is highly advised to use harm reduction practices if using this substance.

History

Chemistry

ETH-LAD

ETH-LAD

ETH-LAD is a structural analog of lysergic acid with an N,N-diethylamide functional group bound to RN of the chemical structure.

This core polycyclic structure is an indole derivative and has both overlapping tryptamine and phenethylamine skeletons embedded within its molecular structure (although it is principally classified as a tryptamine).

ETH-LAD’s structure contains a bicyclic hexahydroindole fused to a bicyclic quinoline group (nor-lysergic acid). ETH-LAD does not contain a methyl group substituted at R6 of its nor-lysergic acid skeleton as is the case with LSD; this is represented by the nor- prefix.

Instead, ETH-LAD is substituted at R6 with an ethyl group.

At carbon 8 of the quinoline, a N,N-diethyl carboxamide is bound in the same configuration of LSD. ETH-LAD is a chiral compound with two stereocenters at R5 and R8.

ETH-LAD, also called (+)-D-ETH-LAD, has an absolute configuration of (5R, 8R).

Common NameN-ETHYLNORLYSERGIC ACID N,N-DIETHYLAMIDE
Systematic nameN-ETHYLNORLYSERGIC ACID N,N-DIETHYLAMIDE
FormulaC_{21}H_{27}N_{3}O
SMILESCCN1C[[email protected]@H](C=C2[[email protected]]1Cc3c[nH]c4c3c2ccc4)C(=O)N(CC)CC
Std. InChiInChI=1S/C21H27N3O/c1-4-23(5-2)21(25)15-10-17-16-8-7-9-18-20(16)14(12-22-18)11-19(17)24(6-3)13-15/h7-10,12,15,19,22H,4-6,11,13H2,1-3H3/t15-,19-/m1/s1
Std. InChiKeyMYNOUXJLOHVSMQ-DNVCBOLYSA-N
Avg. Mass337.4586 Da
Molecular Weight337.4586
Monoisotopic Mass337.215424 Da
Nominal Mass337
ChemSpider ID21106300

Subscribe for the latest updates

Dosing Guide

Oral
Threshold20-30ug
Light30-60ug
Common60-100ug
Strong100-200ug+

Duration

ETH-LAD Duration Data
Onset15-90 minutes
Duration6-14 hours
After-effects1-12 hours

Interactions and Synergies

There are no existing interaction or synergy data for this drug.

General Information

Experiences
Oral
Vaporization
Come up
Dosage
Effects
After Effects
Avoid
Warning
Risks
Test Kits
Marguis Test Result
Tolerance
Detection
Half-life
Advice
Note
Note 2:
Note 3:

Effects

Pharmacological Effects

As with LSD and other compounds in the lysergamide family, ETH-LAD likely acts as a 5-HT2A partial agonist. The psychedelic effects are believed to come from ETH-LAD’s efficacy at the 5-HT2A receptors, although it is likely that like LSD, ETH-LAD also binds to a wide range of different receptors, including multiple different subtypes of serotonin receptors as well as dopamine and adrenoreceptors well. However, the role of these interactions and how they result in the psychedelic experience remains subject to on-going scientific investigation.

Subjective Effects

While the subjective effects of ETH-LAD are reported to largely overlap with those of LSD, it has been noted for the tendency to be more visually and auditorily distortive, introspective, analytical and immersive yet with the capacity to produce pronounced discomforting physical effects like severe and persisting nausea, and temperature dysregulation past the common dose range in a seemingly unpredictable manner.

Physical Effects

  • Stimulation - In terms of its effects on the physical energy levels of the user, ETH-LAD is regarded as being able to produce a spectrum of either predominantly stimulating or sedating effects, often alternating throughout the experience, sometimes to the point of feeling forced. This is in distinction to other, more commonly used psychedelics such as psilocybin which are more consistent in producing sedation and relaxation.
  • Spontaneous bodily sensations - The "body high" of ETH-LAD can be characterized as prominent in comparison to its accompanying visual and cognitive effects. Like LSD, it can behave as a fast-moving, sharp and location specific or generalized tingling sensation, although this feeling is not necessarily pleasant and often manifests in a neutral way. For some, it is manifested spontaneously at different, unpredictable points throughout the experience, but for most, it maintains a steady presence that rises with the onset and hits its limit once the peak has been reached, which users tend to report as feeling "neutral", with the emphasis instead placed on alterations in the "head space".
    • Physical euphoria - This component can occur with the development of spontaneous bodily sensations, but is not as consistent as it is with LSD, and has more of a tendency to spontaneously produce mild to strong neutral if not uncomfortable physical sensations such as those that can be experienced on 2C-E.
  • Bodily pressures - This can manifest as either negative or pleasant bodily sensations capable of occurring anywhere, but particularly in the central areas of the body including the inner cavities like the chest or the lungs.
  • Temperature regulation suppression - This effect can occur with the use of any lysergamide or psychedelic, but reports suggest it may be pronounced in ETH-LAD. It is highly advised that users of this compound, especially at heavier doses, monitor their bodily temperature and use techniques like hot showers or cold packs to regulate their core and brain temperature throughout the experience, and to generally always maintain proximity to a climate-controlled environment.
  • Nausea - In comparison to traditional psychedelics, ETH-LAD has been noted for being able to produce nausea and other "body load" type feelings more readily, potentially at any point during the experience but most prominently during the "come up".
  • Appetite suppression
  • Headaches - This effect typically occurs either spontaneously, or on the comedown of higher doses than is thought the body can handle.
  • Bodily control enhancement
  • Stamina enhancement - This is generally mild in comparison to traditional stimulants.
  • Dehydration - Users are advised to pay careful attention to both their water and electrolyte levels when taking ETH-LAD, being cautious to neither under nor over drink.
  • Difficulty urinating or Frequent urination - While lysergamides are known for their interactions with the kidneys and bladder, ETH-LAD seems to affect it more so than LSD.
  • Increased blood pressure
  • Increased heart rate
  • Increased perspiration
  • Muscle contractions
  • Muscle cramps - This effect can occur with the use of any lysergamide or psychedelic, but reports suggest it can be especially pronounced with this substance.
  • Muscle spasms - This effect can occur with the use of any lysergamide or psychedelic, but reports suggest it can be especially pronounced with this substance.
  • Gustatory hallucination
  • Olfactory hallucination
  • Mouth numbing
  • Excessive yawning
  • Watery eyes
  • Pupil dilation
  • Vasoconstriction
  • Teeth grinding - This effect is considerably less intense when compared with that of substances like MDMA and happens more readily than with related substances like LSD, perhaps owing to the greater degree of stimulation it produces.
  • Seizure - This is an effect whose likelihood is largely extrapolated from the seizures that have been reported from the use of LSD. They are thought to mainly be a risk in those who are genetically predisposed to them, particularly while accompanied by physically taxing conditions such as states of dehydration, fatigue or undernourishment. Although the extent to which this differs from the seizure risk posed by LSD is totally unknown, it is highly advised that users should always be prepared for the worst case scenario.

Psychological Effects

The cognitive effects of ETH-LAD can be broken down into several components which progressively intensify proportional to dosage. In comparison to other psychedelics such as psilocybin mushrooms and ayahuasca, ETH-LAD is often described as significantly more stimulating and fast-paced in terms of the specific style of thought stream(s) produced and contains a large number of potential effects. It should be noted that that higher doses appear to be readily capable of producing cognitive impairment and general sensory processing overload for reasons that are not currently understood. The most prominent of these cognitive effects generally include:

  • Analysis enhancement - This effect seems to be one of the uniquely pronounced features of this substance relative to other chemicals in its class. The kind of analysis enhancement experienced has drawn comparisons to the headspaces of drugs like 2C-E and DOM, with a more emotionally neutral charge than LSD or AL-LAD.
  • Conceptual thinking
  • Thought acceleration - While this effect can occur with the use of any lysergamide psychedelic, reports suggest it can be especially pronounced with this compound until the heavy dose range is reached.
  • Thought connectivity
  • Thought organization
  • Cognitive euphoria
  • Introspection
  • Personal bias suppression
  • Immersion enhancement
  • Novelty enhancement - This component can occur with the use of any lysergamide psychedelic, but reports suggest it can be especially pronounced with this compound.
  • Anxiety & Paranoia - These effects do not occur as commonly at low to moderate doses, particularly when the basic rules of set and setting are taken into account, but can be overwhelming at higher doses. The negative sensations produced by this effect are seemingly more likely to manifest when the substance is combined with cannabis. Therefore, this combination should be used with extreme caution if one is not experienced with psychedelics, meaning that the user should adequately pace themselves while taking only a fraction of their usual amount.
  • Language suppression - This effect can be described as a perceived inability or general unwillingness to talk aloud despite feeling perfectly capable of formulating coherent thoughts within one's internal narrative. It appears to be less prominent at low doses and more prominent at high doses compared to related lysergamides like LSD.
  • Memory suppression - This component and subcomponent may happen more readily and unpredictably than with other psychedelic compounds. For this reason, harm-reduction practices like having a trip sitter arranged beforehand when taking higher doses of this substance are highly advised.
    • Ego death
    • Amnesia - This compound has been reported to produce more amnesic effects than LSD at higher doses.
  • Confusion - Some users have reported that the strong hallucinatory and memory suppressing effects of ETH-LAD at higher doses may lend itself more readily to states of confusion and disorientation than other psychedelics.
  • Increased music appreciation
  • Déjà vu
  • Thought loops - This component can occur with the use of any lysergamide or psychedelic, but reports suggest it can be especially pronounced with ETH-LAD when it does occur.
  • Time distortion - This component has been reported to be particularly pronounced relative to other psychedelics.
  • Multiple thought streams - This component can occur with the use of any lysergamide psychedelic, but reports suggest it can be especially likely to occur with this compound.
  • Wakefulness

Visual Effects

ETH-LAD is reported to produce a remarkable and unique range of visual effects that are often described as "synthetic", "digital", and highly complex in feeling. It has been noted for its capacity to produce profoundly complex visual hallucinations, including higher level geometry, in a much more reliable and consistent manner than other members of the lysergamide family.

Enhancements

The effects listed below are generally considered more pronounced than they are for LSD at equipotent doses.

Distortions

The effects listed below are generally considered to be more pronounced than they are for LSD at equipotent doses.

Geometry

The visual geometry encountered on ETH-LAD can be generally described as more similar in appearance to that of DPT or 2C-E than psilocin, LSA or DMT. It can be comprehensively described through its variations as primarily intricate in complexity, algorithmic in form, structured in organization, brightly lit, colourful in scheme, synthetic in feel, multicoloured in scheme, flat in shading, sharp in edges, large in size, fast in speed, smooth in motion, angular in its corners, immersive in-depth and consistent in intensity. At higher dosages, it may almost consistently result in states of Level 8A or Level 8B visual geometry.

Hallucinatory states

ETH-LAD is capable of producing a full range of low and high level hallucinatory states in a fashion that is significantly less consistent and reproducible than that of many other commonly used psychedelics. These effects include:

Auditory Effects

Auditory effects are reported to be more pronounced with ETH-LAD than for LSD. ETH-LAD has been noted for the sheer depth and range of auditory hallucinations and alterations it is capable of producing, for reasons that are yet poorly understood.

  • Auditory enhancement
  • Auditory hallucination - The audio hallucinations produced by ETH-LAD seem to be more prominent compared to many other psychedelics. The reasons are not yet understood, but those who use this substance are advised to be prepared for the uncontrollable auditory hallucinations it can produce.
  • Auditory distortion - This effect is uniquely pronounced relative to other members of the lysergamide family. At doses above the common dose, they are liable to either be neutral if not mildly disturbing or intriguing.

Sensory Effects

  • Synaesthesia - Many reports suggest that this substance is especially reliable at inducing synaesthetic states in those who are predisposed to them.

Transpersonal Effects

Legal Status

ETH-LAD is currently a gray area compound within many parts of the world. This means that it is not known to be specifically illegal within most countries. People may still be charged for its possession under certain circumstances such as under analogue laws (as an analogue of LSD) and with the intent to sell or consume.

  • Austria: ETH-LAD is technically not illegal but it may fall in the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich) as an analogue of LSD.
  • Germany: ETH-LAD is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
  • Latvia: ETH-LAD is illegal in Latvia. Although ETH-LAD is not officially scheduled, it is controlled as an LSD structural analog due to an amendment made on June 1, 2015.
  • Poland: ETH-LAD is a NPS class drug in Poland, making it illegal to possess or distribute.
  • Switzerland: ETH-LAD is scheduled as of the of December 1, 2015.
  • United Kingdom: As of January 7, 2015, ETH-LAD is specifically named in the U.K. Misuse of Drugs Act as a Class A controlled substance.
  • United States: ETH-LAD is unscheduled in the United States. It may be considered an analogue of LSD (which is a Schedule I compound under the Controlled Substances Act). As such, the sale for human consumption or the use for illicit non-medical or scientific research could be prosecuted as crimes under the Federal Analogue Act.

  • References

    1. "COMPOUND SUMMARY: N-Ethylnorlysergic acid N,N-diethylamide". National Center for Biotechnology Information. CID 44457783. Retrieved May 5, 2017.
    2. Shulgin, Alexander; Shulgin, Ann (1997). "#12. ETH-LAD". TiHKAL: The Continuation. United States: Transform Press.  0-9630096-9-9. OCLC 38503252.
    3. Hoffman, Andrew J.; Nichols, David E. (1985). "Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives". Journal of Medicinal Chemistry. 28 (9): 1252–1255. :10.1021/jm00147a022.  0022-2623.
    4. Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. :10.1007/BF03161089.  1556-9039.
    5. "Anlage NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
    6. "Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes" (PDF). Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27 (in German). Bundesanzeiger Verlag. July 17, 2019. pp. 1083–1094. Retrieved January 1, 2020.
    7. "§ 4 NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
    8. "Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem" (in Latvian). VSIA Latvijas Vēstnesis. November 10, 2005. Retrieved January 1, 2020.
    9. "Rozporządzenie Ministra zdrowia z dnia 21 sierpnia 2019 r. zmieniające rozporządzenie w sprawie wykazu substancji psychotropowych, środków odurzających oraz nowych substancji psychoaktywnych" (PDF) (in Polish).
    10. "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel,psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien: Änderung vom 2. November 2015" (PDF) (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.
    11. Advisory Council on the Misuse of Drugs (June 10, 2014). "Update of the generic definition for tryptamines" (PDF). Government Digital Service. p. 12. Retrieved January 1, 2020.

    Sources

    Information made possible with:

    1. PsychonautWiki is a community-driven online encyclopedia that aims to document the field of psychonautics in a comprehensive, scientifically-grounded manner.
    2. Erowid is a non-profit educational & harm-reduction resource with 60 thousand pages of online information about psychoactive drugs
    3. PubChem National Center for Bio Informatics
    4. Chemspider is a free chemical structure database providing fast access to over 34 million structures, properties and associated information.
    5. Wikipedia

    Additional APIs were used to construct this information. Thanks for ChemSpider, NCBI, PubChem etc.

    Data is constantly updated so please check back later to see if there is any more available information on this substance.